首页> 美国卫生研究院文献>Cancers >Reconsideration of the Appropriate Dissection Range Based on Japanese Anatomical Classification for Resectable Pancreatic Head Cancer in the Era of Multimodal Treatment

【2h】

Reconsideration of the Appropriate Dissection Range Based on Japanese Anatomical Classification for Resectable Pancreatic Head Cancer in the Era of Multimodal Treatment

机译：基于日本解剖学分类对多式联合治疗时代可重置胰头癌的日本解剖学分类的适当解剖范围的重新考虑

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Although the survival benefit of “regional lymph node dissection” for pancreatic head cancer remains unclear, the R0 resection rate is reportedly associated with prognosis. We reviewed the literature that could be helpful in determining the appropriate resection range. The recent development of high-quality computed tomography has made it possible to evaluate the extent of cancer infiltration. Even if the “dissection to achieve R0 resection” range is simulated based on the computed tomography evaluation, it is difficult to identify the range intraoperatively. It is necessary to be aware of the anatomical landmarks to determine the appropriate dissection range intraoperatively.

机译：虽然“区域淋巴结解剖”对胰头癌的生存效果仍不清楚，但据报道，R0切除率与预后有关。我们审查了可能有助于确定适当的切除术范围的文献。最近的高质量计算断层扫描的发展使得可以评估癌症渗透的程度。即使基于计算的断层摄影评估模拟“实现R0切除的分析”范围，难以识别术中的范围。有必要了解解剖标记以术中确定适当的解剖范围。

著录项

期刊名称 Cancers
作者
Yuichi Nagakawa; Naoya Nakagawa; Chie Takishita; Ichiro Uyama; Shingo Kozono; Hiroaki Osakabe; Kenta Suzuki; Nobuhiko Nakagawa; Yuichi Hosokawa; Tomoki Shirota; Masayuki Honda; Tesshi Yamada; Kenji Katsumata; Akihiko Tsuchida;
展开▼
作者单位

展开▼
年(卷),期 2021(13),14
年度 2021
页码 3605
总页数 16
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：胰腺癌;胰腺癌切除术;中脓糖;上肠道动脉;神经和纤维组织;佐剂化疗;淋巴结解剖;R0切除;

相似文献

外文文献
中文文献
专利

1. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: A multi-institutional survey by the Japanese Society of Pancreatic Surgery [J] . KatoH., UsuiM., IsajiS., Journal of hepato-biliary-pancreatic sciences . 2013,第6期

机译：交界性可切除胰腺头/体癌的临床特征和治疗结果：日本胰腺外科学会的多机构调查
2. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. [J] . Fuyuhiko Motoi, Michiaki Unno, Hidenori Takahashi, Journal of hepato-biliary-pancreatic sciences . 2014,第2期

机译：术前抗癌治疗对胰腺癌可切除性和围手术期结局的影响：日本肝胆胰外科协会的研究项目。
3. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. [J] . Fuyuhiko Motoi, Michiaki Unno, Hidenori Takahashi, Journal of hepato-biliary-pancreatic sciences . 2014,第2期

机译：术前抗癌治疗对胰腺癌患者重新分配和围手术期结果的影响：日本肝胆胰腺外科学会的项目研究。
4. SEER Based Pancreatic Cancer Resectability Prediction Tool [C] . Lena Abu-El-Haija, Julie Ivy, Walter Park Institute of Industrial and Systems Engineers Annual Conference and Expo . 2021

机译：基于SER的胰腺癌可重视预测工具
5. Dosimetric Evaluation of VMAT, IMRT, and Proton Treatment Techniques Targeting Borderline Resectable Pancreatic Cancer Lesions [D] . Harpool, Kristyn Brenna. 2017

机译：针对边缘可切除胰腺癌病变的VMAT，IMRT和质子治疗技术的剂量学评估
6. Protocol of a prospective monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study [O] . Susanne Roth, Christoph Springfeld, Markus K Diener, 2019

机译：一项前瞻性单中心I / II期可行性研究的方案该方案研究在术中化疗和手术切除相结合治疗局部局限性或边缘性可切除胰腺癌的多模态治疗的安全性：combiCaRe研究
7. Table 5.5.a.1 Tumor size and treatment (rate of resectability) Figure 5.5.a.2 Cumulative survival of the patients after pancreatectomy for TS1 cancer according to residual tumors Figure 5.5.a.3 Cumulative survival of the patients with TS1 cancer according to extent of lymph node dissection Figure 5.5.a.4 Combined resection of portal vein and cumulative survival of the patients after pancreatectomy for TS1 cancer of UICC Stage IIa or IIb in the pancreatic head Figure 5.5.a.5 Combined resection of peripancreatic plexus and cumulative survival of the patients after pancreatectomy for TS1 cancer of UICC Stage IIa or IIb in the pancreatic head Figure 5.5.a.6 Combined resection of peripancreatic plexus when there is no plexus infiltration and cumulative survival of the patients after pancreatectomy for TS1 cancer of UICC Stage IIa or IIb in the pancreatic head Figure 5.5.a.7 Combined resection of artery and cumulative survival of the patients after pancreatectomy for TS1 cancer of UICC Stage IIa or IIb in the pancreatic head Figure 5.5.a.8 Combined resection of portal vein and cumulative survival of the patients after pancreatectomy for TS2 (2.1-4.0 cm) cancer of UICC Stage IIa or IIb in the pancreatic head Figure 5.5.a.9 Combined resection of peripancreatic plexus and cumulative survival of the patients after pancreatectomy for TS2 (2.1-4.0 cm) cancer of UICC Stage IIa or IIb in the pancreatic head [O] . 2007

机译：表5.5.a.1肿瘤大小和治疗（重新切性率）图5.5.a.2根据残留肿瘤对TS1癌胰腺切除后患者的累积存活图5.5.A.3累积存活根据淋巴结解剖的程度，TS1癌症的患者图5.5.A.4在胰头胰腺IIA或IIB癌症术后胰岛切除术后的门静脉和累积患者的累积存活图5.5。 A.5在胰头术后IIA或IIB胰腺切除术后，患者胰腺癌丛和患者累积存活的组合图5.5.A.6当没有丛浸润时，围裙丛生的围嘴巴丛的切除胰腺切除术后胰腺切除术后胰腺炎癌症的累积存活图5.5.A.7在TS1癌症胰腺切除后患者的动脉和累积存活的组合UICC阶段IIA或IIB在胰头图5.5.A.8在胰头胰腺阶段IIA或IIB癌症的胰腺切除后，患者的门静脉和累积患者的累积存活率图5.5.A.9在胰头胰腺阶段IIA或IIB的胰腺切除术后胰腺切除术后患者患者患者患者的累积生存的组合和胰腺头

Reconsideration of the Appropriate Dissection Range Based on Japanese Anatomical Classification for Resectable Pancreatic Head Cancer in the Era of Multimodal Treatment

摘要

著录项

相似文献

相关主题

期刊订阅